Emerging standardization in pharmacoeconomics

Area of Science:

• Health Economics
• Pharmacoeconomics
• Health Policy

Background:

• Pharmacoeconomic evaluations are crucial for healthcare decision-making.
• International guidelines aim to standardize these assessments.
• Varying guidelines can lead to inconsistencies in economic evaluations.

Purpose of the Study:

• To identify areas of emerging standardization in pharmacoeconomic guidelines.
• To compare and contrast key elements across international pharmacoeconomic guidelines.
• To understand the factors influencing the evolution of economic guidelines.

Main Methods:

• Systematic review of pharmacoeconomic guidelines from six countries (UK, Spain, Italy, Australia, Canada, US).
• Analysis of published literature, journal guidelines, and task force recommendations.
• Comparative analysis of common principles and divergent topics across guidelines.

Main Results:

• Consensus exists on transparent methods, bias minimization, and justification of assumptions.
• Key differences identified in assessment type, perspective, comparators, data sources, analysis, outcomes, modeling, time horizon, discounting, disclosure, and generalizability.
• Emerging standardization focuses on methodological transparency.

Conclusions:

• Pharmacoeconomic guidelines are evolving with a tension between increasing consistency and validity.
• Achieving a balance between consistency and validity is essential for robust economic assessments.
• Further harmonization is needed in specific areas to improve comparability of evaluations.